Herein, we aimed to identify the immunomodulatory role of tumor Syndecan-1 (CD138) in the polarization of CD4 + T helper (Th) subsets isolated from the tumor microenvironment of inflammatory breast cancer (IBC) and non-IBC patients. Lymphocytes and mononuclear cells isolated from the axillary tributaries of non-IBC and IBC patients during modified radical mastectomy were either stimulated with the secretome as indirect co-culture or directly cocultured with control and Syndecan-1-silenced SUM-149 IBC cells. In addition, peripheral blood mononuclear cells (PBMCs) of normal subjects were used for the direct co-culture. Employing flow cytometry, we analyzed the expression of the intracellular IFN-γ, IL-4, IL-17, and Foxp3 markers as readout for basal and co-cultured Th 1 , Th 2 , Th 17 , and T reg CD4 + subsets, respectively. Our data revealed that IBC displayed a lower basal frequency of Th 1 and Th 2 subsets than non-IBC. Syndecan-1-silenced SUM-149 cells significantly upregulated only T reg subset polarization of normal subjects relative to controls. However, Syndecan-1 silencing significantly enhanced the polarization of Th 17 and T reg subsets of non-IBC under both direct and indirect conditions and induced only Th 1 subset polarization under indirect conditions compared to control. Interestingly, qPCR revealed that there was a negative correlation between Syndecan-1 and each of IL-4, IL-17, and Foxp3 mRNA expression in carcinoma tissues of IBC and that the correlation was reversed in non-IBC. Mechanistically, Syndecan-1 knockdown in SUM-149 cells promoted Th 17 cell expansion via upregulation of IL-23 and the Notch ligand DLL4. Overall, this study indicates a low frequency of the circulating antitumor Th 1 subset in IBC and suggests that tumor Syndecan-1 silencing enhances ex vivo polarization of CD4 + Th 17 and T reg cells of non-IBC, whereby Th 17 polarization is possibly mediated via upregulation of IL-23 and DLL4. These findings suggest the immunoregulatory role of tumor Syndecan-1 expression in Th cell polarization that may have therapeutic implications for breast cancer.
Introduction
Female breast cancer is the most broadly diagnosed cancer heading the list of life-threatening cancers in women all over the world and in Egypt [1, 2] . Inflammatory breast cancer (IBC) is a deadly aggressive form of breast cancer that is featured by enrichment of cancer stemness, rapid invasion into the dermal lymphatic vasculature, increasing metastasis, and low survival rate in comparison to non-IBC [3, 4] . One of the mechanistic clues for the clinical and pathological features of IBC are the components of the tumor microenvironment that can crosstalk with IBC cells either directly through cell-cell physical interactions [5] or indirectly via soluble paracrine mediators [6] to maintain tumor growth and escape immunosurveillance [7, 8] .
In a previous study, we have detected a chronic inflammatory breast cancer microenvironment enriched with a high frequency of T helper cells (CD4 + T cells) that are considered to be important immune players within the tumor microenvironment [9] . CD4 + T cells can be polarized into paradoxical subsets; Th 1 , Th 2 , Th 17 , and T reg in response to various signaling mediators [10] . The Th 1 subset typically produces IFN-γ to enhance the cytotoxic activity of tumor-specific CD8 + T cells [11] . The Th 2 subset produces the classical anti-inflammatory cytokines IL-4, IL-13, and IL-5, to activate the M 2 macrophage protumor phenotype and increase metastasis potential of breast carcinoma [12] . The Th 17 subset primarily produces IL-17A to promote proliferation, metastasis, and drug resistance of breast carcinoma [13, 14] . Finally, the Foxp3 + regulatory T cells (T reg ) that create an immunosuppressive tumor microenvironment, allowing escape from immunosurveillance, and consequently, enhancing breast carcinoma progression [15, 16] . CD4 + T cells are highly plastic cells that can be inter-converted between different subsets according to cytokines and chemokines milieu of the environment [17] .
One of the key molecules that are implicated in the modulation of inflammatory cytokines and chemokines, as well as the progression of breast carcinoma, is the heparan sulfate (HS) proteoglycan Syndecan-1 (Sdc-1; CD138) [3, 18] . In breast carcinoma, the differential expression and molecular functions have been assigned to Sdc-1 in the context of its stromal/cancer cell expression and/or its membrane-bound/shedding forms [19] [20] [21] . Recently, we have demonstrated that relative to non-IBC, carcinoma tissue of IBC confers a higher expression of Sdc-1 mRNA and protein that is associated with the expression of Notch as well as the unique cancer stemness phenotype of IBC [3] . On the other side, various studies provide evidence that ligand engagement with Notch receptor on the surface of Th cells can orchestrate the differentiation of Th subsets through regulation of their genetic signature [22] . Furthermore, Sdc-1 can inhibit T cell driven inflammation through sequestration of T cell-specific CC chemokines in a HS-dependent mechanism [23] [24] [25] . Accordingly, Sdc-1 depletion has been shown to modulate the expression of IL-17 and IFN-γ in natural killer T (NKT) cells during thymic development [26] . All these studies pinpoint an important role for Sdc-1 in reprogramming the soluble mediators that consequently shape the cellular composition of the inflammatory environment. Therefore, this prompted us to investigate the frequency of different T helper subsets drained from the tumor microenvironment of non-IBC and IBC through axillary tributaries. Moreover, we sought to unravel the potential unexplored immunomodulatory role played by Sdc-1 in modulating the polarization of CD4 + T cells isolated from non-IBC and IBC patients.
containing 5% fetal calf serum (FCS), 1% glutamine and 1% penicillin/streptomycin in a humidified atmosphere of 5% CO 2 at 37˚C. All cell culture supplies were purchased from Lonza (MD, USA), unless otherwise stated.
siRNA-mediated silencing of Sdc-1 expression
A total of 3.5 x 10 5 SUM-149 cells were subjected to Sdc-1 silencing as we previously described [3] . Successful knockdown was confirmed by quantitative PCR (qPCR) and flow cytometry [27, 28] .
Preparation of media conditioned by the secretome of control and Sdc-1-silenced SUM-149 cells
For preparation of conditioned media (CM), 48 h post transfection control and Sdc-1-silenced SUM-149 cells were cultivated in serum free HAM's-F12 media in a humidified atmosphere of 5% CO 2 at 37˚C for 24 hours. CM was collected, centrifuged at 1500 rpm for 5 min to remove cell debris and stored at −80˚C for stimulation experiments.
Patient samples
This study was approved by the research ethics committee of Ain Shams University, Cairo, Egypt (IRB#00006379), and has been conducted in accordance with the ethical standards of the 1964 Helsinki declaration. A written informed consent to participate in this study and to publish data was obtained from 55 female patients who were diagnosed with breast cancer and received primary surgery at breast clinic of Ain Shams University. Patients were divided into 2 groups: non-IBC (n = 34) and IBC (n = 21). During modified radical mastectomy, carcinoma tissues and 10 mL blood drained from tumor microenvironment to the venous circulation of the breast through axillary tributaries was collected in EDTA tubes as we described previously [9] . Normal breast tissues were collected during reduction mammoplatsty from healthy volunteers.
Immunophenotyping of axillary CD4 + T cell subsets of non-IBC and IBC patients
Blood mononuclear cells were separated from axillary tributaries by Ficoll-hypaque density gradient according to manufacturer's instructions. Briefly, whole blood was diluted with equal volume phosphate buffered saline (PBS) before Ficoll density gradient centrifugation. The buffy coat containing the mononuclear cells was harvested and red blood cells (RBCs) were lysed by incubation in ammonium chloride potassium (ACK) lysing buffer. Afterwards, the mononuclear cells were washed twice with cold PBS and monocytes were depleted by adherence to a plastic surface at 37˚C for 2 hours [29] , whereas the non-adherent lymphocytes were isolated and resuspended as 1 x 10 6 cells/ml RPMI 1640 supplemented with 10% FCS, 1% glutamine, and 1% penicillin/ streptomycin for immunophenotyping by flow cytometry.
Stimulation of T-lymphocytes by the secretome of control and Sdc-1-silenced SUM-149 cells
To elucidate the effect of tumor Sdc-1 expression on the polarization of CD4 + T cells, we activated the isolated lymphocytes with plate bound anti-CD3 (10 μg/ml; clone: MEM-57), and soluble anti-CD28 (0.5 μg/ml; clone: 15E8) (Immunotools, Friesoythe, Germany), in complete RPMI 1640 medium containing 30% CM of control and Sdc-1-silenced SUM-149 cells for 96 h. The optimal concentration of CM was selected based on our pilot experiments. 
Direct co-culture of mononuclear cells with control and Sdc-1-silenced SUM-149 cells

Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and immunoblotting
Briefly, total cell lysates of control and Sdc-1 siRNA transfected SUM-149 cells were prepared as described before [3] . Protein concentration was determined using Bradford assay and 50 ug protein per lane were electrophoresed on 10% SDS-PAGE and electrotransferred into nitrocellulose membrane (Millipore, Germany). After blocking with 5% BSA in tris-buffered saline with 0.1% tween (TBST) for 1 hour the membrane was probed with 2 ug/mL primary antibody against DLL4 (Santa Cruz Biotech, CA, USA) overnight at 4˚C. On the next day, the membrane was incubated with 1 ug/mL anti-mouse secondary antibody conjugated with horseradish peroxidase (Santa Cruz Biotech, CA, USA) for 1 hour at room temperature. The immunoreactivity was visualized by Enhanced Chemiluminescence (ECL) reaction and BioSpectrum 815 Imaging System (Analytik Jena, USA). β-actin (Santa Cruz Biotech) was used as a loading control.
Statistical analysis
Statistical analysis was performed using IBM SPSS version 18 (Chicago, IL, USA). Fisher's exact test was used to evaluate differences between variables. Two groups' comparisons were evaluated for normally distributed data using Student's t test, and for non-normally distributed data using Mann-Whitney U-test. Correlations were conducted using Spearman's Rank correlation test. Two-tailed P values were considered significant at P < 0.05. The data were represented as mean ± SEM.
Results
Clinical and pathological patient characteristics
We recruited 34 non-IBC and 21 IBC patients and their clinic-pathological criteria are depicted in Table 1 . Carcinoma tissue of IBC patients showed a significant increased incidence of �4 positive metastatic lymph nodes (P = 0.005) as well as a higher lymphovascular invasion (P = 0.001) as compared to non-IBC patients.
Low frequency of circulating Th 1 and Th 2 CD4 + T cell subsets in blood drained from the tumor microenvironment of IBC compared to non-IBC patients
We have previously detected a significant elevation in the proportion of CD4 + T cells drained from the tumor microenvironment of breast cancer patients through axillary tributaries in comparison with peripheral blood [9] . In this study we further characterized CD4 + T cell sub- ) using multicolor flow cytometry. Our data indicate that the frequency of the Th 1 subset was significantly higher in non-IBC patients by 61.6% than in IBC patients (with an average 29.6 ± 3.9% in non-IBC, and 11.38 ± 0.7% in IBC patients, P = 0.01) (Fig 1, Table 2 ).
Similarly, a significantly increased Th 2 subset in non-IBC patients by 56.6% compared with IBC was observed (with an average 28.29 ± 3.87% in non-IBC, and 12.28 ± 1.43% in IBC patients, P = 0.03) (Fig 1, Table 2 ). Strikingly, the Th 17 subset represented the predominant subset among different CD4 + T cell subsets, constituting more than 30% of the isolated CD4 + T cells in non-IBC (30.37%, with an average 33.86 ± 5.27%, n = 10) and IBC patients (37.82%, with an average 26.18 ± 4.64%, n = 4) ( Table 2) , although there was no significant difference between non-IBC and IBC patients (Fig 1) . Also, the Foxp3 + (T reg ) cell subset ranked as the second highest proportion of CD4 + T cells in IBC patients representing 23.1%
(with an average 16.71 ± 4.06%, n = 4), whereas it ranked as the lowest proportion of CD4 + T cells in non-IBC patients representing 14.56% (with an average 16.15 ± 2.84%, n = 10), although there was no significant difference between non-IBC and IBC patients (Fig 1 , Table 2 ).
Syndecan-1 (CD138) and T helper cell polarization in breast cancer patients
Tumor Sdc-1 silencing significantly favors polarization of Th 1 , Th 17 and T reg subsets in non-IBC patients population was altered by 26.7% (with an average 25.3 ± 3.5% in control cells, and 30.8 ± 4.2% upon Sdc-1 silencing, P = 0.001, n = 15), the Th 17 population by 17.2% (with an average 27.4 ± 4.2% in control cells, and 31.9 ± 5.2% upon Sdc-1 silencing, P = 0.02, n = 15), and Th 1 cells by 11.6% (with an average of 37.05 ± 5.07% in control cells and 40.63 ± 5.46% upon Sdc-1 silencing, P = 0.001, n = 15) (Fig 2a-2c , Table 3 ) as compared to control. (Fig 2c  and 2d , Table 4 ).
Further, in a direct co-culture of normal PBMCs with control and Sdc-1-silenced SUM-149 cells, we detected only a significantly increased percentage in the T reg (Foxp3 + CD4 + ) subset by 35.66% (with an average 22.61 ± 3.21% in control cells, and 28.98 ± 2.56% upon Sdc-1 silencing, P = 0.04, n = 5) (Fig 3d, Table 4 ), whereas there were no significant alterations in the percentage of other subsets as compared to the negative control (Fig 3a-3c, Table 4 ). https://doi.org/10.1371/journal.pone.0217550.g003
On the contrary, no significant change in the percentages of Th 2 , Th 17 and T reg subsets of IBC patients was observed when stimulated with the secretome of Sdc-1-silenced SUM-149 cells in comparison to that of control (S2 Fig, Table 3 ). Only the percentage of the Th 1 (IFN-γ + CD4 + ) subset increased by 9.22% but it did not reach the significance level (P = 0.2, n = 5) (S2 Fig, Table 3) . Interestingly, the Th 1 /Foxp3 + T reg ratio was increased from 1.5 to 2.18 upon stimulation with the secretome of control and Sdc-1-silenced SUM-149 cells (Table 3) , suggesting a skewing of CD4 + T cell polarization towards the Th 1 subset as functional effector cells.
Carcinoma tissues of IBC display an inverse correlation between expression of Sdc-1 and each of IL-4, IL-17, and Foxp3 mRNA levels
We next investigated the clinical relevance of our in vitro data. Therefore, we examined expression of IL-17, Foxp3, IL-4 and Sdc-1 transcript levels in carcinoma tissue of non-IBC and IBC patients and tested whether there is any correlation among them. Interestingly, our qPCR data demonstrate a significantly negative correlation between expression of Sdc-1 and IL-4 (r = -0.564, P = 0.028), IL-17 (r = -0.571, P = 0.026), and Foxp3 (r = -0.607, P = 0.016) in breast carcinoma tissues of IBC patients (Fig 4) . In contrast, a significantly positive correlation between expression of Sdc-1 and IL-4 (r = 0.554, P = 0.032), IL-17 (r = 0.7, P = 0.004), and Foxp3 (r = 0.539, P = 0.038) was evident in breast carcinoma tissues of non-IBC (Fig 4) . 
Sdc-1 knockdown drives Th 17 skewing possibly via upregulation of IL-23 and DLL4 in SUM-149 cells
We next sought to delineate the potential molecular mechanism(s) exerted by Sdc-1 in regulating Th17 subset. One of the key cytokines that enhance the expansion of Th 17 cells in inflammatory microenvironment is IL-23 [30] . Thus, we investigated the effect of Sdc-1 silencing on the transcript level of IL-23 in SUM-149 cells. Our qPCR data revealed that Sdc-1 silencing significantly upregulated IL-23 mRNA expression (P = 0.01) in comparison to control cells (Fig  5a) . Since the Notch ligand delta-like 3 and 4 (DLL3 and 4), provides additional skewing signals to drive the polarization of IL-17 producing Th17 cells [22, 31] , we therefore examined whether Sdc-1 silencing might affect the expression of DLL3 and 4 in SUM-149 cells using qPCR and Western blot. Relative to controls, DLL4 was significantly upregulated at the mRNA level in Sdc-1-silenced SUM-149 cells (P = 0.0036) (Fig 5b) , as well as at the protein level (Fig 5c) . However, DLL3 mRNA expression was not altered (data not shown). We further examined expression of TGF-β mRNA (for Th17 and Foxp3 polarization [32] ) by qPCR, as well as TLR4 mRNA and protein expression (for Foxp3 + T reg polarization [33] ) by qPCR and
Western blotting, respectively in SUM-149 cells after Sdc-1 silencing. Our data did not reveal any significant difference for their expression upon Sdc-1 suppression (Data not shown).
Discussion
Due to the unique aggressive nature of IBC, it is speculated to be integrated with a characteristic tumor microenvironment that enhances its aggressive behavior. Mounting evidence pointed to the unfavorable effect of the reciprocal interactions between breast cancer cells and Syndecan-1 (CD138) and T helper cell polarization in breast cancer patients stromal cells nested in the tumor microenvironment, which allow the advance of breast carcinoma phenotype from being in situ to be invasive and spread to lymph nodes and distant tissues [4] . In this study, we extended our previous findings demonstrating increased CD4 + T cells drained from tumor microenvironment of breast cancer patients [9] by evaluating the different CD4 + T cell subsets isolated from non-IBC and IBC patients. Our data revealed that the Th 17
(IL-17
) subset is the predominant subset among CD4 + T cells in both groups; non-IBC and IBC patients. This is consistent with the previous study reported that a high proportion of Th 17 subset is a common feature between several cancer entities, including breast carcinoma [34] . Furthermore, our results showed that IBC patients are characterized by a high frequency of the T reg (Foxp3 + CD4 + ) subset representing 23% of total CD4 + T cells drained from the ) subset in IBC patients may represent a factor that contributes to the aggressive behavior of IBC, based on the fact that Th 1 subset are typically the effector cells that mediate the main anti-cancer response [11, 35] , whereas the elevated proportion of the T reg (Foxp3 + CD4 + ) subset suppresses the anti-cancer immune response developing immune tolerance of cancer cells, and thus promote progression and aggressiveness of the cancer [36] .
Surprisingly, we have detected a significant high frequency of Th 2 cells in axillary blood of non-IBC patients in comparison with IBC patients. Although there was a high expression of IL-4 mRNA in carcinoma tissues of IBC vs non-IBC, it did not reach the significance level. It has been reported that Th 2 type tumor microenvironment can promote tumor metastasis [12] , and resistance to chemotherapy and radiotherapy [37] . On the contrary, other studies have reported that loss of GATA-3 expression, a master transcriptional regulator of Th 2 specific cytokines [38] , has been associated with aggressive tumor phenotype and worse prognosis in breast cancer patients [39, 40] . Therefore, these conflicting data needs further validation in a large cohort of patients with a determination of IL-4 expression localization in infiltrated Th cells vs. tumor cells.
As Sdc-1 displays the capacity to bind different ligands involving cell surface, matrix proteins, growth factors, cytokines, and chemokines, it emerges as a candidate modulator of inflammatory processes [41] . Sdc-1 expression is upregulated in human breast carcinoma tissue, and its overexpression is correlated with cancer aggressiveness and poor prognosis [42] . Moreover, we have previously demonstrated that relative to non-IBC, carcinoma tissue of IBC confers a higher expression of Sdc-1 mRNA and protein that are associated with the unique cancer stemness phenotype of IBC [3] . Despite the growing evidence connecting chronic inflammation to breast cancer progression [43, 44] , to our knowledge this is the first study investigating the impact of tumor Sdc-1 silencing on polarization of T helper cells towards Th 1 , Th 2 , Th 17 , and T reg subsets isolated from non-IBC and IBC breast cancer patients. Our results revealed that tumor Sdc-1 silencing promotes the proportion of Th 1 (IFN-γ + CD4 + ) subset of non-IBC patients when stimulated with the secretome of Sdc-1-silenced SUM-149 cells but not in direct co-culture, as compared to negative control. Moreover, we noted an increased Th 1 /T reg ratio in CD4 + T cells isolated from IBC patients upon stimulation with the secretome of Sdc-1-silenced SUM-149 cells in comparison to control, indicating a skewing of the polarization towards the Th 1 subset. These findings can be explained based on the previous notion that the HS chains of Sdc-1 competitively inhibit IFN-γ binding to its receptor [45, 46] , and consequently, inhibit its biologic activity [45, 47] . Further, we previously demonstrated reduced levels of IL-6 in conditioned media of SUM-149 cells upon Sdc-1silencing [3] . IL-6 is a pleiotropic cytokine that is able to interfere with IFN-γR signaling and to inhibit the gene expression of IFN-γ and Th 1 polarization [48] . Taken studies demonstrated that Sdc-1 can bind and inhibit TGF-β responsiveness [52] [53] [54] [55] . Moreover, it binds and downregulates its activator protein, Thrombospondin-1 (TSP-1) [53, 56] . Additional data demonstrate that Sdc-1 knockdown increases surface expression of αvβ 6 integrin, activating latent TGF-β complex, and constitutively elevating TGF-β signaling [57] . While TGF-β is critical for polarization of the T reg (Foxp3 + CD4 + ) subset, IL-6 negatively regulates the generation of T reg cells induced by TGF-β [58] . We have shown that in breast cancer cells specifically IBC, silencing of Sdc-1 drives downregulation of IL-6 and its signaling pathway components [27, 59] . Although TGF-β mRNA expression was not altered after Sdc-1 knockdown, we can speculate that Sdc [60] . Similarly, Sdc-1 knockout mice showed an increase in the frequency of NKT 17 cells during thymic development [26] . On the contrary, the expression of Sdc-1 is positively correlated with that of IL-17 in nasal epithelial cells, glandular epithelial cells, and inflammatory cells of nasal polyps [61] . Therefore, the conflicting reports in different experimental systems suggest that Sdc-1 may modulate polarization of Th 17 subset in the context of the pathophysiological state. IL-23 is a key cytokine that plays important roles in the pathogenesis of inflammatory diseases through the activation and expansion of Th 17 cells [30] . Indeed, our data demonstrated an upregulation of IL-23 mRNA expression in Sdc-1-silenced SUM-149 cells as compared to control. As an additional clue for driving Th 17 skewing, we detected an upregulation of DLL4 expression at the transcript and protein levels in Sdc-1-silenced SUM-149 cells relative to control cells. DLL4 is a key Notch ligand that engages Notch receptor on T cell surface activating Notch signaling [22, 62] . The gene promotors of Rorc, IL-17, and IL-23-receptor are direct Notch targets [31, 63] and, accordingly, DLL4 provides additional Th 17 skewing signals through upregulation of RORγt [31] . Taken together, this provides a possible mechanistic explanation for the enhancement of Th 17 cell expansion via upregulation of IL-23 and DLL4 after suppression of Sdc-1 expression on IBC cells. Given the pro-or anti-tumor functions of Th 17 cells [64] , the exact function of [31] .
In conclusion, our study demonstrates lower frequencies of circulating Th 1 , and Th 2 subsets in axillary tributaries of IBC than that of non-IBC patients (Fig 6) . Moreover, we demonstrate that tumor Sdc-1 silencing enhances the polarization of Th cells under indirect conditions towards Th 1 and under both co-culture conditions towards Th 17 , and T reg subsets, but not towards Th 2 subset in non-IBC. However, tumor Sdc-1 silencing does not alter the polarization of Th cells towards a particular subset, but increases only the Th 1 /T reg ratio indicating a skewing of the polarization towards Th 1 subset in IBC. Moreover, there is a negative correlation between expression of Sdc-1 mRNA and IL-4, IL-17 and Foxp3 mRNA levels in carcinoma tissues of IBC and that correlation was reversed in non-IBC. Mechanistically, Sdc-1 silencing mediates Th 17 cells expansion possibly via upregulation of IL-23 and DLL4 (Fig 6) . 
